Adarx Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Main-fund capital flow has been a net inflow over the last 36 sessions.
- Short interest has risen to 1.8% of float.
- Analyst tilt is Buy.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Key statistics
Price & volume
- Prev close
- 14.16
- Open
- 14.03
- Day range
- 12.63 - 14.87
- Avg price
- 13.57
- Volume
- 708.83K
- Turnover
- 9.62M
- Turnover ratei
- 3.24%
- Volume ratioi
- 1.12
- Amplitudei
- 15.82%
- 52-week rangei
- 12.50 - 23.21
Valuation
- P/Ei
- -13.19
- P/E (TTM)i
- -13.98
- P/Bi
- 2.48
- EPSi
- -0.97
- Book value / shi
- 5.17
- Net profit
- -107.86M
- Net assets
- 574.43M
Share structure
- Market cap
- 1.42B
- Float capi
- 279.78M
- Shares out
- 111.19M
- Float sharesi
- 21.88M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-09-25
44.9% below the 52-week high
Trading activity
Net capital flow main funds, last 36 sessions
+147.92K net over the window
Short interest
- Shares short
- 1.80M
- % of floati
- 1.76%
- Days to coveri
- 5.02
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Adarx Pharmaceuticals (ADRX)?
Adarx Pharmaceuticals last traded at 12.79. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Adarx Pharmaceuticals's market cap?
About 1.42B.
What is the P/E ratio of Adarx Pharmaceuticals?
The trailing twelve-month P/E is -13.98. The Valuation tab shows it against the stock's own five-year range.
Does Adarx Pharmaceuticals pay a dividend?
Adarx Pharmaceuticals does not currently pay a regular dividend.
Is Adarx Pharmaceuticals a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 35.00, which implies 173.7% upside from the current price. This is not investment advice.
What is Adarx Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Adarx Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.
Adarx Pharmaceuticals discussion 0 comments